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ER-ALPHA AND ER-BETA GENOTYPES PREDICT TAMOX-
IFEN EFFECTS ON SERUM LIPIDS IN BREAST CANCER PA-
TIENTS. M. I. Rehman, MD, A. Bermes, BSc, K. Lee, MD, PhD, T.
Skaar, PhD, M. Arefayene, L. Li, PhD, V. Stearns, MD, D. A.
Flockhart, MD, PhD, D. F. Hayes, MD, Indiana University School of
Medicine, Sungkyunkwan University School of Medicine, John Hop-
kins, University of Michigan, Indianapolis, IN.
Therapy with tamoxifen has been shown to be associated with
favorable changes in lipid profile. We examined the relationship
between genetic polymorphisms in estrogen receptor genes (ER-
alpha and ER-beta) and serum lipid profile in 82 women who were
prescribed tamoxifen (20mg/day). The fasting serum lipid profiles
were evaluated before starting tamoxifen therapy and at the end of
four months of treatment. Pvu II and Xba I RFLPs were used to
identify the IVS1-401 and IVS1-354 polymorphisms of ER-alpha.
Genotyping for the ER-beta single nucleotide polymorphism located
in 3 UTR (dbSNP ID: rs4986938) was performed by a TaqMan
assay. After four months of tamoxifen therapy all women had sig-
nificantly lower LDL-cholesterol compared to baseline and the effect
appeared more pronounced in postmenopausal women (p0.03 and
0.0001 for pre- and postmenopausal women respectively). In the
postmenopausal women, those with ER-alpha IVS1-401 C/C geno-
type had significantly lower total and LDL-cholesterol when com-
pared to those with C/T and T/T genotypes (p 0.014 and 0.017 for
total cholesterol and LDL-cholesterol respectively). In the subgroup
of postmenopausal women with ER-alpha IVS1-401 C/C genotype,
those carrying ER-beta G/G genotype (dbSNP ID: rs4986938) had
the most augmented response of LDL-cholesterol to tamoxifen ther-
apy when compared to other groups (p0.03). This pattern of geno-
types may identify a group of women most likely to experience
cardiovascular benefits from tamoxifen.
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ARG389GLY BETA-1 ADRENERGIC RECEPTOR POLY-
MORPHISM AND LEFT VENTRICULAR REMODELING
CHANGES TO BETA-BLOCKER THERAPY. S. G. Terra,
PharmD, K. K. Hamilton, MD, D. F. Pauly, MD, PhD, C. R. Lee,
PharmD, J. Patterson, PharmD, K. F. Adams, Jr, MD, R. S. Schofield,
MD, J. A. Hill, MD, J. M. Aranda, MD, H. N. Yarandi, PhD, J. A.
Johnson, PharmD, University of Florida, University of North Caro-
lina, Gainesville, FL.
The 1-adrenergic receptor (1AR) contains a common functional
polymorphism at codon 389 (Arg389Gly). In vitro studies indicate
that Arg389 has greater basal and agonist stimulated adenylyl cyclase
activity. We hypothesized that the Arg389Gly polymorphism was
associated with left ventricular (LV) remodeling changes to a
-blocker. We prospectively enrolled 47 -blocker naı¨ve patients
with ischemic or non-ischemic heart failure (HF). Patients received
metoprolol CR/XL (MXL) 12.5-25 mg/d, titrated q 2 weeks (as
tolerated) up to 200 mg/d or highest tolerated dose over 8 weeks.
Patients completed a 2D echocardiogram at baseline and at the end of
study, which occurred 3 months after attainment of highest tolerated
MXL dose during titration. An ANCOVA with baseline measures
and MXL dose as covariates was used to compare changes in ejection
fraction (EF), LV end-diastolic and end-systolic diameters (LVEDD
and LVESD, respectively), between genotypes. The % of patients
with non-ischemic HF, HF duration, and heart rate reduction was
similar between genotypes. The final MXL dose was 136 mg/d for
Arg389Arg and 103 mg/d for Gly389 carriers. Gly389 carriers ex-
perienced progressive ventricular dilatation reflected by increases in
LVEDD and LVESD, while patients with the Arg389Arg genotype
had an attenuation of LV remodeling. The difference in LVEDD was
statistically significant between groups. In conclusion, the codon 389
genotype is associated with LV remodeling changes from -blocker
therapy.
Arg389Arg (n20) Gly389 Carriers
(n27)
P*Baseline Final Baseline Final
EF (%) 24  6 29  11 22  8 23  11 0.15
LVEDD
(mm)
62  12 61  11 63  9 66  9 0.01
LVESD
(mm)
53  11 51  13 54  10 56  12 0.12
*For comparison of change from baseline between genotypes.
Means  SD.
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LACK OF DEVELOPMENT OF ACUTE TOLERANCE (AT)
TO INTRAVENOUS (IV) ETHANOL (ETH) IN THE ELDERLY.
P. W. Slattum, PharmD, PhD, V. A. Ramchandani, PhD, J. Venitz,
MD, PhD, Virginia Commonwealth University, National Institute on
Alcohol Abuse and Alcoholism, Richmond, VA.
AT is defined as a decrease in effect with prolonged exposure
during the time course of a single dose. Development of AT to the
perception of intoxication has been reported after ETH administration
in young persons. Since the elderly have less CNS reserve, it is
hypothesized that they will not develop AT to the same degree as the
young. This study was designed to evaluate AT development in the
elderly. Eight men (mean age 72.4 yr; range 70-82 yr) and 7 women
(mean age 74.9 yr; range 69-88 yr) underwent pharmacokinetic (PK)
screening to determine individual PK characteristics and estimate
ETH doses to achieve and sustain serum ETH concentrations (SEC)
at a target of 1000 mg/L. Later, they received a 1-hr IV ETH infusion
to achieve target SEC, followed by a 5-hr IV ETH infusion to
maintain target SEC. SEC was measured by TDx/TDxFlx. The phar-
macodynamic (PD) effect was measured by a subject-rated impair-
ment (SRI) scale and number vigilance speed (NVS). The degree of
AT was estimated using PK-PD modeling. Vdss was lower in the
elderly (males 0.38 L/kg; females 0.36 L/kg) than reported for the
young, supporting earlier findings. AT to SRI was noted in only 4 of
15 elderly compared to 14 of 16 young volunteers studied in the same
laboratory. NVS showed no AT; sensitivity was similar to the young,
but baseline performance was lower in the elderly. The elderly appear
to develop AT to the subjective effects of ETH to a lesser degree/at
a slower rate than the young.
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